Switch to:
More From Other Websites
Baxter Submits Application for U.S. FDA Approval of BAX111, Investigational Recombinant Treatment... Dec 22 2014
9:01 am Baxter announces thatit has submitted a BLA to the FDA for the approval of BAX111 Dec 22 2014
Baxter Submits Application for U.S. FDA Approval of BAX111, Investigational Recombinant Treatment... Dec 22 2014
Baxter Submits Application for U.S. FDA Approval of BAX111, Investigational Recombinant Treatment... Dec 22 2014
Baxter to Present at 33rd Annual J.P. Morgan Healthcare Conference Dec 18 2014
Baxter to Present at 33rd Annual J.P. Morgan Healthcare Conference Dec 18 2014
Baxter International Fourth Quarter 2014 Financial Results Conference Call Dec 17 2014
BAXTER INTERNATIONAL INC Files SEC form 8-K, Creation of a Direct Financial Obligation or an... Dec 16 2014
Baxter to Divest Vero Cell Vaccines Platform to Nanotherapeutics Dec 15 2014
Baxter to Divest Vero Cell Vaccines Platform to Nanotherapeutics Dec 15 2014
[video]Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan Dec 12 2014
Baxter Files Form 10 with SEC, Advances Baxalta Spin-off Dec 11 2014
Nektar/AstraZeneca's Moventig Gets EU Approval for OIC Dec 10 2014
Baxter Announces Filing of Form 10 Registration Statement in Connection with Planned Spin off of... Dec 10 2014
Baxter Announces Filing of Form 10 Registration Statement in Connection with Planned Spin off of... Dec 10 2014
Baxter’s Culture of Community Engagement and Inclusion Recognized by Leading Organizations Dec 09 2014
Baxter’s Culture of Community Engagement and Inclusion Recognized by Leading Organizations Dec 09 2014
Baxter: Strong Sell on Prevailing Headwinds, Estimate Revision Dec 05 2014
Video Release -- Preclinical Research Differentiating the Activity of Merrimack's MM-398,... Dec 04 2014
Baxter Files BLA for BAX 855 in Hemophilia A Treatment Dec 02 2014


Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

Sww
ReplySww - 5 months ago
Bax medical devices revenue ~9b, bio science ~7b
using 3X sales of medical devices company and 4X for drugs company, 27b+28b = 55b market cap,as of June 2014, BAX market cap is 39b, so it can sell for

72 * (1 + 16/39) = 99

72 is current stock price, with an upside of around 35%

so my guess is BAX may be able to sell for around 90 after spin-off.


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK